Goldline Pharmaceutical Ltd
₹
- close price
About
Goldline Pharmaceuticals is engaged in the business of marketing pharmaceutical products under the brand name “Goldline.”[1]
Key Points
- Market Cap ₹ 41.3 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 14.2
- Book Value ₹
- Dividend Yield %
- ROCE 29.2 %
- ROE 39.7 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 31.2%
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 19.73 | 23.48 | 28.01 | |
| 17.32 | 19.14 | 21.86 | |
| Operating Profit | 2.41 | 4.34 | 6.15 |
| OPM % | 12.21% | 18.48% | 21.96% |
| -0.20 | -0.04 | -0.09 | |
| Interest | 1.63 | 1.61 | 1.95 |
| Depreciation | 0.18 | 0.16 | 0.25 |
| Profit before tax | 0.40 | 2.53 | 3.86 |
| Tax % | 37.50% | 28.46% | 26.42% |
| 0.26 | 1.81 | 2.83 | |
| EPS in Rs | 1.30 | 7.87 | 4.10 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 19% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 58% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 31% |
| Last Year: | 40% |
Balance Sheet
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Equity Capital | 2.00 | 2.30 | 6.90 |
| Reserves | 2.08 | 3.76 | 1.65 |
| 12.64 | 12.94 | 12.85 | |
| 2.67 | 3.93 | 4.88 | |
| Total Liabilities | 19.39 | 22.93 | 26.28 |
| 2.50 | 2.95 | 2.89 | |
| CWIP | 0.00 | 0.45 | 0.00 |
| Investments | 0.07 | 0.03 | 0.04 |
| 16.82 | 19.50 | 23.35 | |
| Total Assets | 19.39 | 22.93 | 26.28 |
Cash Flows
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 2.39 | 2.92 | 2.32 | |
| -1.04 | -1.11 | 0.16 | |
| -1.44 | -1.08 | -2.03 | |
| Net Cash Flow | -0.09 | 0.74 | 0.45 |
| Free Cash Flow | 1.38 | 1.81 | 2.49 |
| CFO/OP | 101% | 72% | 53% |
Ratios
Figures in Rs. Crores
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 159.65 | 149.54 | 139.30 |
| Inventory Days | 336.20 | 450.39 | 229.14 |
| Days Payable | 54.47 | 98.62 | 69.62 |
| Cash Conversion Cycle | 441.39 | 501.32 | 298.82 |
| Working Capital Days | 143.74 | 132.76 | 134.74 |
| ROCE % | 23.40% | 29.21% |
Documents
Annual reports
No data available.
Business Profile:[1]
Goldline Pharmaceutical is engaged in the marketing and distribution of pharmaceutical products under the “Goldline” brand through
an asset-light, third-party manufacturing model. The company does not manufacture products
in-house; instead, it partners with contract manufacturers for production while focusing
on product selection, branding, distribution, marketing, and supply chain management.